Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) announced a conference call to discuss its 2021 fourth quarter and year-end financial results on February 11, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The press release will precede this at 4:30 a.m. PT. Investors can access the call via domestic (800-895-3361) and international (785-424-1062) dial-in numbers, using Conference ID: NBIX. A replay will be available on Neurocrine's website following the event, highlighting the company's commitment to addressing neurological and psychiatric disorders through its diverse portfolio and ongoing clinical programs.

Positive

• Scheduled conference call for Q4 and year-end 2021 financial results indicates transparency.
• Company's focus on life-changing treatments for serious disorders shows long-term growth potential.

Negative

• None.

SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on Friday, February 11, 2022.

The schedule for the press release and conference call / webcast is as follows:

Q4 & Year-End 2021 Press Release:	February 11, 2022 at 4:30 a.m. PT / 7:30 a.m. ET
Q4 & Year-End 2021 Conference Call:	February 11, 2022 at 5:00 a.m. PT / 8:00 a.m. ET
Domestic Dial-In Number:	800-895-3361
International Dial-In Number:	785-424-1062
Conference ID:	NBIX

The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2021-financial-results-301467978.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What is the date and time for Neurocrine Biosciences' Q4 2021 financial results conference call?

The conference call is scheduled for February 11, 2022, at 5:00 a.m. PT (8:00 a.m. ET).

How can I access the Neurocrine Biosciences Q4 2021 financial results press release?

The press release will be available on February 11, 2022, at 4:30 a.m. PT, on Neurocrine's website.

What is the dial-in number for the Neurocrine Biosciences conference call?

The domestic dial-in number is 800-895-3361 and the international number is 785-424-1062.

Where can I find the webcast of the Neurocrine Biosciences conference call?

The webcast can be accessed on Neurocrine's website under the Investors section.

Will there be a replay of the Neurocrine Biosciences conference call?

Yes, a replay will be available on the website approximately one hour after the conclusion of the event.